Zealand Pharma: Additional positive results from global Phase III program with lixisenatide for Type 2 Diabetes
Results show potential for an improved blood glucose level during the day, further supporting the promising therapeutic profile of lixisenatide
15-Apr-2011 -
Zealand Pharma announced the release by its partner, sanofi-aventis, of positive top-line results from the GetGoal-S Phase III study of lixisenatide, a once-daily GLP-1 agonist in development for patients with Type 2 diabetes. In the study, lixisenatide achieved the primary efficacy endpoint of ...
Sanofi-aventis
type 2 diabetes